{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:56:30Z","timestamp":1787003790908,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Midline CNS tumors are occasionally inaccessible for surgical biopsies. In these instances, cell-free DNA (cfDNA) may serve as a viable alternative for molecular analysis and identification of targetable mutations. Here, we report a young child with an inoperable brainstem tumor in whom a stereotactic biopsy was deemed unsafe. The tumor progressed on steroids and after radiotherapy the patient developed hydrocephalus and received a ventriculoperitoneal shunt. Droplet digital PCR analysis of cfDNA from an intraoperative cerebrospinal fluid liquid biopsy revealed a\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600 mutation enabling targeted treatment with MEK and BRAF inhibitors. The patient, now on trametinib and dabrafenib for 1 year, has had substantial tumor volume regression and reduction of contrast enhancement on MRIs and is making remarkable clinical progress. This case highlights that in a subset of CNS tumors, access to liquid biopsy analysis may be crucial to identify actionable therapeutic targets that would otherwise go undiscovered.\n                  <\/jats:p>","DOI":"10.1038\/s41698-024-00535-8","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T13:02:47Z","timestamp":1708606967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Liquid biopsy guides successful molecular targeted therapy of an inoperable pediatric brainstem neoplasm"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-6530","authenticated-orcid":false,"given":"Cecilia","family":"Arthur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena-Maria","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5546-1017","authenticated-orcid":false,"given":"Jan","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Sandvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Jylh\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Nordenskj\u00f6ld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"535_CR1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noac161","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 24, iii1\u2013iii38 (2022).","journal-title":"Neuro Oncol."},{"key":"535_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11910-023-01257-3","volume":"23","author":"SF Sait","year":"2023","unstructured":"Sait, S. F., Giantini-Larsen, A. M., Tringale, K. R., Souweidane, M. M. & Karajannis, M. A. Treatment of pediatric low-grade gliomas. Curr. Neurol. Neurosci. Rep. 23, 185\u2013199 (2023).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"535_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/cncr.29907","volume":"122","author":"R Krishnatry","year":"2016","unstructured":"Krishnatry, R. et al. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer 122, 1261\u20131269 (2016).","journal-title":"Cancer"},{"key":"535_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","volume":"8","author":"S Ryall","year":"2020","unstructured":"Ryall, S., Tabori, U. & Hawkins, C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol. Commun. 8, 30 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"535_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"535_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1158\/2159-8290.CD-21-1094","volume":"12","author":"SM Pfister","year":"2022","unstructured":"Pfister, S. M. et al. A summary of the inaugural WHO classification of pediatric tumors: transitioning from the optical into the molecular era. Cancer Discov. 12, 331\u2013355 (2022).","journal-title":"Cancer Discov."},{"key":"535_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.2014.58.3922","volume":"33","author":"M Mistry","year":"2015","unstructured":"Mistry, M. et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J. Clin. Oncol. 33, 1015\u20131022 (2015).","journal-title":"J. Clin. Oncol."},{"key":"535_CR8","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1200\/JCO.2016.71.8726","volume":"35","author":"A Lassaletta","year":"2017","unstructured":"Lassaletta, A. et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J. Clin. Oncol. 35, 2934\u20132941 (2017).","journal-title":"J. Clin. Oncol."},{"key":"535_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","volume":"37","author":"S Ryall","year":"2020","unstructured":"Ryall, S. et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37, 569\u2013583.e5 (2020).","journal-title":"Cancer Cell"},{"key":"535_CR10","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","volume":"25","author":"DR Hargrave","year":"2019","unstructured":"Hargrave, D. R. et al. Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I\/IIa study. Clin. Cancer Res. 25, 7303\u20137311 (2019).","journal-title":"Clin. Cancer Res."},{"key":"535_CR11","doi-asserted-by":"publisher","unstructured":"Nobre, L. et al. Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis. Oncol. 4 https:\/\/doi.org\/10.1200\/po.19.00298 (2020).","DOI":"10.1200\/po.19.00298"},{"key":"535_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1200\/JCO.22.01000","volume":"41","author":"E Bouffet","year":"2023","unstructured":"Bouffet, E. et al. Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma. J. Clin. Oncol. 41, 664\u2013674 (2023).","journal-title":"J. Clin. Oncol."},{"key":"535_CR13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet, E. et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N. Engl. J. Med. 389, 1108\u20131120 (2023).","journal-title":"N. Engl. J. Med."},{"key":"535_CR14","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah, V. et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 21, 1234\u20131243 (2020).","journal-title":"Lancet Oncol."},{"key":"535_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah, V. et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann. Oncol. 33, 406\u2013415 (2022).","journal-title":"Ann. Oncol."},{"key":"535_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","volume":"23","author":"PY Wen","year":"2022","unstructured":"Wen, P. Y. et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 23, 53\u201364 (2022).","journal-title":"Lancet Oncol."},{"key":"535_CR17","unstructured":"FDA. FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation#:~:text=On%20March%2016%2C%202023%2C%20the,mutation%20who%20require%20systemic%20therapy (2023)."},{"key":"535_CR18","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00381-020-04658-8","volume":"36","author":"J Soleman","year":"2020","unstructured":"Soleman, J., Kozyrev, D. A., Ben-Sira, L., Constantini, S. & Roth, J. Management of incidental brain tumors in children: a systematic review. Childs Nerv. Syst. 36, 1607\u20131619 (2020).","journal-title":"Childs Nerv. Syst."},{"key":"535_CR19","doi-asserted-by":"publisher","first-page":"e639","DOI":"10.1016\/j.wneu.2020.10.147","volume":"146","author":"H Faulkner","year":"2021","unstructured":"Faulkner, H. et al. The surgical resection of brainstem glioma: outcomes and prognostic factors. World Neurosurg. 146, e639\u2013e650 (2021).","journal-title":"World Neurosurg."},{"key":"535_CR20","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00381-015-2832-1","volume":"31","author":"S Puget","year":"2015","unstructured":"Puget, S. et al. Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas. Childs Nerv. Syst. 31, 1773\u20131780 (2015).","journal-title":"Childs Nerv. Syst."},{"key":"535_CR21","unstructured":"Grill, J. Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE). https:\/\/clinicaltrials.gov\/study\/NCT02233049 (2014)."},{"key":"535_CR22","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/neuonc\/noac035","volume":"24","author":"AM Miller","year":"2022","unstructured":"Miller, A. M. et al. Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. Neuro Oncol. 24, 1763\u20131772 (2022).","journal-title":"Neuro Oncol."},{"key":"535_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/neuonc\/noac004","volume":"24","author":"R Soffietti","year":"2022","unstructured":"Soffietti, R. et al. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. Neuro Oncol. 24, 855\u2013871 (2022).","journal-title":"Neuro Oncol."},{"key":"535_CR24","doi-asserted-by":"publisher","first-page":"e404770","DOI":"10.1200\/EDBK_404770","volume":"43","author":"MA Gouda","year":"2023","unstructured":"Gouda, M. A. & Subbiah, V. Expanding the benefit: dabrafenib\/trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors. Am. Soc. Clin. Oncol. Educ. Book 43, e404770 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"535_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6442-2","volume":"19","author":"S Perreault","year":"2019","unstructured":"Perreault, S. et al. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01. BMC Cancer 19, 1250 (2019).","journal-title":"BMC Cancer"},{"key":"535_CR26","unstructured":"NCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (2017)."},{"key":"535_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fonc.2015.00054","volume":"5","author":"CL Penman","year":"2015","unstructured":"Penman, C. L., Faulkner, C., Lowis, S. P. & Kurian, K. M. Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas. Front. Oncol. 5, 54 (2015).","journal-title":"Front. Oncol."},{"key":"535_CR28","unstructured":"Sweden\u2019s national accreditation body (SWEDAC). https:\/\/www.swedac.se\/?lang=en (2023)."},{"key":"535_CR29","unstructured":"European Consortium for Histiocytosis (ECHO). https:\/\/www.echo-histio.net\/ (2023)."},{"key":"535_CR30","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Romero, N. et al. BRAF V600E detection in liquid biopsies from pediatric central nervous system tumors. Cancers 12 https:\/\/doi.org\/10.3390\/cancers12010066 (2019).","DOI":"10.3390\/cancers12010066"},{"key":"535_CR31","doi-asserted-by":"publisher","unstructured":"Nobre, L. et al. Validation of a liquid biopsy tool to identify point mutations in pediatric brain tumor patients. Cancer Res. 79 https:\/\/doi.org\/10.1158\/1538-7445.SABCS18-2226 (2019).","DOI":"10.1158\/1538-7445.SABCS18-2226"},{"key":"535_CR32","doi-asserted-by":"publisher","first-page":"AA88","DOI":"10.1093\/neuonc\/noz036.103","volume":"21","author":"AK Eterovic","year":"2019","unstructured":"Eterovic, A. K. et al. A robust cell-free DNA (CFDNA) assay to detect mutations in plasma samples of pediatric high grade glioma patients despite genomic DNA (GDNA) contamination. Neuro Oncol. 21, AA88 (2019).","journal-title":"Neuro Oncol."},{"key":"535_CR33","doi-asserted-by":"publisher","first-page":"e28651","DOI":"10.1002\/pbc.28651","volume":"67","author":"Y Nakano","year":"2020","unstructured":"Nakano, Y. et al. Utility of a bridged nucleic acid clamp for liquid biopsy: detecting BRAF V600E in the cerebrospinal fluid of a patient with brain tumor. Pediatr. Blood Cancer 67, e28651 (2020).","journal-title":"Pediatr. Blood Cancer"},{"key":"535_CR34","doi-asserted-by":"publisher","first-page":"100819","DOI":"10.1016\/j.mam.2019.09.003","volume":"72","author":"D Andersson","year":"2020","unstructured":"Andersson, D., Fagman, H., Dalin, M. G. & St\u00e5hlberg, A. Circulating cell-free tumor DNA analysis in pediatric cancers. Mol. Asp. Med. 72, 100819 (2020).","journal-title":"Mol. Asp. Med."},{"key":"535_CR35","first-page":"58","volume":"9","author":"JC Melms","year":"2018","unstructured":"Melms, J. C. et al. Implementation of cell-free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: a case report. Mol. Clin. Oncol. 9, 58\u201361 (2018).","journal-title":"Mol. Clin. Oncol."},{"key":"535_CR36","doi-asserted-by":"publisher","first-page":"e04551","DOI":"10.1002\/ccr3.4551","volume":"9","author":"M Natsumeda","year":"2021","unstructured":"Natsumeda, M. et al. Less-invasive diagnosis of disseminated epithelioid glioblastoma harboring BRAF V600E mutation by cerebrospinal fluid analysis\u2014a case report. Clin. Case Rep. 9, e04551 (2021).","journal-title":"Clin. Case Rep."},{"key":"535_CR37","doi-asserted-by":"publisher","first-page":"688200","DOI":"10.3389\/fonc.2021.688200","volume":"11","author":"J Jiang","year":"2021","unstructured":"Jiang, J. et al. Case report: Vemurafenib treatment in brain metastases of BRAF(S365L)-mutant lung papillary cancer by genetic sequencing of cerebrospinal fluid circulating tumor DNA detection. Front. Oncol. 11, 688200 (2021).","journal-title":"Front. Oncol."},{"key":"535_CR38","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/neuonc\/noad032","volume":"25","author":"M Kojic","year":"2023","unstructured":"Kojic, M. et al. Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening. Neuro Oncol. 25, 1507\u20131517 (2023).","journal-title":"Neuro Oncol."},{"key":"535_CR39","doi-asserted-by":"publisher","first-page":"899325","DOI":"10.3389\/fonc.2022.899325","volume":"12","author":"C Arthur","year":"2022","unstructured":"Arthur, C. et al. Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia: a proof of concept study. Front. Oncol. 12, 899325 (2022).","journal-title":"Front. Oncol."},{"key":"535_CR40","doi-asserted-by":"publisher","unstructured":"Arthur, C. et al. Simultaneous ultra-sensitive detection of structural and single nucleotide variants using multiplex droplet digital PCR in liquid biopsies from children with medulloblastoma. Cancers 15 https:\/\/doi.org\/10.3390\/cancers15071972 (2023).","DOI":"10.3390\/cancers15071972"},{"key":"535_CR41","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen, C. E. et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 1914\u20131922 (2009).","journal-title":"Neurology"},{"key":"535_CR42","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/neuonc\/noz156","volume":"21","author":"AK Mattox","year":"2019","unstructured":"Mattox, A. K., Yan, H. & Bettegowda, C. The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors. Neuro Oncol. 21, 1509\u20131518 (2019).","journal-title":"Neuro Oncol."},{"key":"535_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13040607","volume":"13","author":"JY Tan","year":"2021","unstructured":"Tan, J. Y., Wijesinghe, I. V. S., Kamarudin, M. N. A. & Parhar, I. Paediatric gliomas: BRAF and histone H3 as biomarkers, therapy and perspective of liquid biopsies. Cancers 13, 1\u201318 (2021).","journal-title":"Cancers"},{"key":"535_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84513-1","volume":"11","author":"D Li","year":"2021","unstructured":"Li, D. et al. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR. Sci. Rep. 11, 5098 (2021).","journal-title":"Sci. Rep."},{"key":"535_CR45","doi-asserted-by":"publisher","unstructured":"Maass, K. K. et al. From sampling to sequencing: a liquid biopsy pre-analytic workflow to maximize multi-layer genomic information from a single tube. Cancers 13 https:\/\/doi.org\/10.3390\/cancers13123002 (2021).","DOI":"10.3390\/cancers13123002"},{"key":"535_CR46","doi-asserted-by":"publisher","first-page":"101292","DOI":"10.1016\/j.xpro.2022.101292","volume":"3","author":"APY Liu","year":"2022","unstructured":"Liu, A. P. Y., Smith, K. S., Kumar, R., Robinson, G. W. & Northcott, P. A. Low-coverage whole-genome sequencing of cerebrospinal-fluid-derived cell-free DNA in brain tumor patients. STAR Protoc. 3, 101292 (2022).","journal-title":"STAR Protoc."},{"key":"535_CR47","unstructured":"The European Society for Paediatric Oncology (SIOPE). https:\/\/siope.eu\/SIOPE-Brain-Tumour-Group (2023)."},{"key":"535_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00381-015-2968-z","volume":"32","author":"P Steinbok","year":"2016","unstructured":"Steinbok, P. et al. Pediatric thalamic tumors in the MRI era: a Canadian perspective. Childs Nerv. Syst. 32, 269\u2013280 (2016).","journal-title":"Childs Nerv. Syst."},{"key":"535_CR49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00401-018-1936-6","volume":"137","author":"C Pan","year":"2019","unstructured":"Pan, C. et al. Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. Acta Neuropathol. 137, 297\u2013306 (2019).","journal-title":"Acta Neuropathol."},{"key":"535_CR50","doi-asserted-by":"publisher","first-page":"e12881","DOI":"10.15252\/emmm.202012881","volume":"13","author":"F Mouliere","year":"2021","unstructured":"Mouliere, F. et al. Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. EMBO Mol. Med. 13, e12881 (2021).","journal-title":"EMBO Mol. Med."},{"key":"535_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.tig.2023.01.004","volume":"39","author":"T Moser","year":"2023","unstructured":"Moser, T., K\u00fchberger, S., Lazzeri, I., Vlachos, G. & Heitzer, E. Bridging biological cfDNA features and machine learning approaches. Trends Genet. 39, 285\u2013307 (2023).","journal-title":"Trends Genet."},{"key":"535_CR52","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat. Med. 29, 1103\u20131112 (2023).","journal-title":"Nat. Med."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00535-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00535-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00535-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T23:39:15Z","timestamp":1708645155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00535-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1038\/s41698-024-00535-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"6 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}